Arkin Bio Ventures
VC Fund
Herzliya, Israel
Arkin Bio Ventures is a VC fund in Herzliya focused on Biotechnology and Health Care. Arkin Holdings is dedicated to empowering companies that create breakthrough pharma, biotech and medical device technologies.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Arkin Bio Ventures invests in
Stages Arkin Bio Ventures invests in
Countries Arkin Bio Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $11M–$125M
- Series B
- $13M–$80M
- Series C
- $19M–$182M
Investment Focus
Industry
- Biotechnology 16 (67%)
- Health Care 8 (33%)
- Therapeutics 8 (33%)
- Medical 5 (21%)
- Life Science 4 (17%)
Stage
- Series A 12 (50%)
- Series B 7 (29%)
- Series C 3 (13%)
- Seed 1 (4%)
Country
- United States 9 (38%)
- Israel 4 (17%)
- Canada 1 (4%)
- Norway 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Pini Orbach
Managing Partner
|
Managing Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ambros Therapeutics
|
Ambros Therapeutics is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases. | $125M / Series A / Dec 16, 2025 | |
Reunion Neuroscience
|
Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications. | $133M / Series A / Sep 16, 2025 | |
Actithera
|
Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows. | $75.5M / Series A / Jul 09, 2025 | |
Newleos Therapeutics
|
Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines. | $93.5M / Series A / Feb 13, 2025 | |
Auron Therapeutics
|
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $27.3M / Series B / Feb 04, 2025 | |
Bluejay Therapeutics
|
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate offunctional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients. | $182M / Series C / May 09, 2024 | |
Entact Bio
|
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins. | $81M / Series A / Dec 06, 2022 | |
Photys Therapeutics
|
Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein post-translational modifications, going beyond degradation to restore protein function, repair signaling, and amplify endogenous disease-fighting mechanisms. Photys was co-founded by the Broad Institute’s leading bifunctional chemist, AmitChoudhary, and the Longwood Fund, alongside a scientific advisory board comprised of distinguished scientists and drug developers – MIT’s Angela Koehler, Salk’s Tony Hunter, Berkeley’s Dan Nomura, MPM’s Wendy Young, and Dana Farber’s Eric Fischer. | $75M / Series A / Sep 08, 2022 | |
|
Bluejay Therapeutics
|
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate offunctional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients. | $41M / Series B / Aug 16, 2022 | |
|
Auron Therapeutics
|
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $48M / Series A / Jul 20, 2022 | |
| See all 24 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Arkin Bio Ventures invest in?
Arkin Bio Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Arkin Bio Ventures's check size?
Arkin Bio Ventures typically joins rounds of $11M–$125M at Series A, $13M–$80M at Series B and $19M–$182M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Arkin Bio Ventures participates in.
How do I contact Arkin Bio Ventures?
Public channels for Arkin Bio Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Arkin Bio Ventures?
The team at Arkin Bio Ventures includes Pini Orbach (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
